Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Technol Adv Mater ; 22(1): 449-460, 2021 Jun 22.
Article in English | MEDLINE | ID: mdl-34211334

ABSTRACT

To realize a sustainable society, 'green technology' with low (or even zero) CO2 emissions is required. A key material in such technology is a permanent magnet because it is utilized for electric-power conversion in several applications including electric vehicles (EVs), hybrid EVs (HEVs), and turbines for wind power generation. To realize highly efficient electric-power conversion, a stronger permanent magnet than Nd-Fe-B is necessary. One potential candidate is a Fe-rich SmFe12-based compound with a ThMn12 structure. In this paper, the phase stability, structure, and intrinsic and extrinsic magnetic properties in both film and bulk forms are reviewed. Based on these results, a possible way to realize a strong SmFe12-based permanent magnet in bulk form is discussed.

2.
Eur J Neurol ; 27(1): 100-104, 2020 01.
Article in English | MEDLINE | ID: mdl-31309642

ABSTRACT

BACKGROUND AND PURPOSE: Tapering immunosuppressants is desirable in patients with well-controlled myasthenia gravis (MG). However, the association between tapering of calcineurin inhibitor dosage and reduction-associated exacerbation is not known. The aim of this study was to clarify the frequency of reduction-associated exacerbation when tacrolimus is tapered in stable patients with anti-acetylcholine receptor antibody-positive MG, and to determine the factors that predict exacerbations. METHODS: We retrospectively analyzed 115 patients in whom tacrolimus dosage was tapered. The reduction-associated exacerbation was defined as the appearance or worsening of one or more MG symptoms <3 months after the reduction. RESULTS: Tacrolimus dosage was successfully tapered in 110 patients (96%) without any exacerbation. Five patients (4%) experienced an exacerbation, but symptoms were reversed in all patients when the tacrolimus dose was increased to the previous maintenance level. No patient developed an MG crisis. The age at onset was significantly earlier (30 vs. 56 years, P = 0.025) and the reduction in dosage was significantly larger (2.0 vs. 1.0 mg/day, P = 0.002) in patients with reduction-associated exacerbation than in those without exacerbation. The cut-off values determined in a receiver-operating characteristic curve analysis were 52 years (sensitivity, 57%; specificity, 100%) for the age at onset and 1.5 mg (sensitivity, 80%; specificity, 100%) for the dose reduction. CONCLUSION: Tapering of tacrolimus was possible in most patients with well-controlled anti-acetylcholine receptor antibody-positive MG. Early age at onset and a large reduction from maintenance dosage were associated with exacerbation. Reductions ≤1.5 mg/day from the maintenance dosage should be considered for patients with late-onset disease.


Subject(s)
Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Myasthenia Gravis/drug therapy , Myasthenia Gravis/immunology , Receptors, Cholinergic/immunology , Tacrolimus/administration & dosage , Tacrolimus/therapeutic use , Adult , Age of Onset , Antibodies/analysis , Drug Tapering , Female , Humans , Immunosuppressive Agents/adverse effects , Male , Middle Aged , ROC Curve , Retrospective Studies , Sensitivity and Specificity , Tacrolimus/adverse effects
3.
Nat Commun ; 9(1): 1035, 2018 03 07.
Article in English | MEDLINE | ID: mdl-29515124

ABSTRACT

"The technical support from SLAC Accelerator Directorate, Technology Innovation Directorate, LCLS laser division and Test Facility Division is gratefully acknowledged. We thank S.P. Weathersby, R.K. Jobe, D. McCormick, A. Mitra, S. Carron and J. Corbett for their invaluable help and technical assistance. Research at SLAC was supported through the SIMES Institute which like the LCLS and SSRL user facilities is funded by the Office of Basic Energy Sciences of the U.S. Department of Energy under Contract No. DE-AC02-76SF00515. The UED work was performed at SLAC MeV-UED, which is supported in part by the DOE BES SUF Division Accelerator & Detector R&D program, the LCLS Facility, and SLAC under contract Nos. DE-AC02-05-CH11231 and DE-AC02-76SF00515. Use of the Linac Coherent Light Source (LCLS), SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515."and"Work at BNL was supported by DOE BES Materials Science and Engineering Division under Contract No: DE-AC02-98CH10886. J.C. would like to acknowledge the support from National Science Foundation Grant No. 1207252. E.E.F. would like to acknowledge support from the U.S. Department of Energy (DOE), Office of Basic Energy Sciences (BES) under Award No. DE-SC0003678."This has been corrected in both the PDF and HTML versions of the Article.

4.
Nat Commun ; 9(1): 388, 2018 01 26.
Article in English | MEDLINE | ID: mdl-29374151

ABSTRACT

Magnetostriction, the strain induced by a change in magnetization, is a universal effect in magnetic materials. Owing to the difficulty in unraveling its microscopic origin, it has been largely treated phenomenologically. Here, we show how the source of magnetostriction-the underlying magnetoelastic stress-can be separated in the time domain, opening the door for an atomistic understanding. X-ray and electron diffraction are used to separate the sub-picosecond spin and lattice responses of FePt nanoparticles. Following excitation with a 50-fs laser pulse, time-resolved X-ray diffraction demonstrates that magnetic order is lost within the nanoparticles with a time constant of 146 fs. Ultrafast electron diffraction reveals that this demagnetization is followed by an anisotropic, three-dimensional lattice motion. Analysis of the size, speed, and symmetry of the lattice motion, together with ab initio calculations accounting for the stresses due to electrons and phonons, allow us to reveal the magnetoelastic stress generated by demagnetization.

5.
Science ; 345(6202): 1337-40, 2014 Sep 12.
Article in English | MEDLINE | ID: mdl-25147280

ABSTRACT

The interplay of light and magnetism allowed light to be used as a probe of magnetic materials. Now the focus has shifted to use polarized light to alter or manipulate magnetism. Here, we demonstrate optical control of ferromagnetic materials ranging from magnetic thin films to multilayers and even granular films being explored for ultra-high-density magnetic recording. Our finding shows that optical control of magnetic materials is a much more general phenomenon than previously assumed and may have a major impact on data memory and storage industries through the integration of optical control of ferromagnetic bits.

6.
Nat Neurosci ; 3(10): 1035-43, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11017177

ABSTRACT

Psychophysical studies indicate that structural features of odorants differentially influence their perceived odor. In the olfactory bulb (OB), odorants are represented by ensembles of activated glomeruli. Here we used optical imaging of intrinsic signals to examine how these structural features are represented spatially in the sensory map of the rat OB. We found that the dorsal OB contained two topographically fixed domains; constituent glomeruli in each domain could be activated by odorants with particular functional groups. Within each domain, other structural features such as carbon chain length and branching were represented by local differences in patterns. These results suggest that structural features are categorized into two classes, primary features (functional groups) that characterize each domain, and secondary features that are represented by local positions within each domain. Such hierarchical representations of different structural features correlate well with psychophysical structure-odor relationships.


Subject(s)
Neurons/cytology , Neurons/drug effects , Olfactory Bulb/cytology , Olfactory Bulb/drug effects , Receptors, Odorant/chemistry , Smell/physiology , Action Potentials/drug effects , Action Potentials/physiology , Animals , Brain Mapping , Molecular Conformation , Molecular Structure , Odorants/analysis , Olfactory Bulb/physiology , Rats , Rats, Sprague-Dawley , Receptors, Odorant/drug effects , Receptors, Odorant/physiology , Signal Transduction/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...